Healthcare & Life Sciences

“They grasp the client’s needs quickly and provide accurate and thorough feedback within the timex-frame. Plus, their interdepartmental collaboration is hugely helpful.”

- Chambers & Partners Asia-Pacific

Overview

BKL’s Healthcare & Life Sciences Group offers a full spectrum of legal services to both international and domestic clients across the healthcare, pharmaceutical, and life sciences industries. With a multidisciplinary team of experts, BKL specializes in key sectors including medical service, pharmaceuticals, medical devices, animal drugs, food and cosmetics.  Our team provides strategic guidance in areas such as regulations, patents and licensing, litigation, government investigations, fair trade, M&A and initial public offerings (IPO). 

BKL has a distinguished track record in addressing complex  regulatory and compliance issues.  Our services include obtaining product approvals, navigating Good Manufacturing Practice (GMP) surveillance, handling violations of the Act on Fair Labeling and Advertising, advising on relevant regulations including inclusion on the National Health Insurance benefit list.  We have also achieved landmark victories in litigation involving  government administrative actions such as sales suspension, drug price reductions, and impurity-related disputes. 

As the healthcare sector evolves into a next-generation industrial driving force, BKL continues to pioneer innovative solutions to support its growth and globalization. Our expertise extends beyond traditional legal services, providing tailored advice on M&A, IPO, overseas expansion, technology licensing, and new business model designs for pharmaceutical and medical device companies and healthcare institutions. In today’s rapidly advancing technological landscape, BKL is at the forefront of addressing emerging challenges and opportunities. We deliver cutting-edge legal and strategic support in areas relating to medical records, use of big data, use of AI and cutting-edge technology, telemedicine, and new drug development. 

Key Services

Regulatory Advice and Litigation on Healthcare Industry Regulations

Handle investigations by health authorities such as the Ministry of Food and Drug Safety and the Ministry of Health and Welfare.
Advise and represent clients in cases concerning the national lot release system.
Manage cases involving temporary manufacturing/sales/use suspension orders, business suspension orders, and other regulatory sanctions.

Legislative and Government Relations Support

Advise on healthcare-related laws such as the Medical Service Act and the Pharmaceutical Affairs Act.
Assist with government legislation and policy consultation.
Monitor health authority trends, obtain authoritative interpretations, and manage interactions with administrative agencies concerning amendments to laws and regulations.

National Health Insurance Advice and Litigation

Provide guidance on the application of healthcare benefits for pharmaceuticals and medical devices, as well as claims for such benefits.
Advise on drug pricing and reimbursement standards, including those related to the launch of biosimilars.
Represent clients in litigation seeking:

Cancellation of ex officio adjustments to drug pricing due to kickback allegations or re-evaluation of additional amounts for drugs.
Cancellation of public notices regarding reductions in medical benefits (e.g., for CT, MRI).
Declarations of no obligation against the National Health Insurance Service concerning impurity detections.

Digital Healthcare Support

Advise and represent clients on the use and management of personal medical data.
Provide legal counsel on telemedicine, digital therapeutic devices, and related technologies.

Compliance and Risk Management

Assist in establishing internal regulations and conducting compliance diagnoses for domestic and international companies.
Conduct internal investigations and employee training to enhance compliance practices.

Technology Licensing and Intellectual Property Rights

Advise and represent clients in cases involving patent and trademark infringement, invalidation, and employee inventions.
Provide counsel on licensing agreements for new drugs and drug candidates.

Healthcare Business Strategy and Corporate Legal Services

Advise on joint ventures, M&A, equity investments, and business transfers between domestic and international pharmaceutical companies.
Represent clients in cases involving the acquisition of foreign hospitals by domestic corporations.
Counsel on contracts such as joint development agreements, exclusive sales agreements, and consignment manufacturing agreements.

Operation of Medical Institutions

Represent clients in litigation related to the establishment and operation of foreign medical institutions, including cancellation or revocation of permissions.
Provide legal support for sanctions, such as suspension of healthcare benefit payments and recovery of benefits.
 

Representative Cases

Represented 36 pharmaceutical companies in a lawsuit against the National Health Insurance Service in connection with reimbursement for Valsartan
Responded to the Ministry of Food and Drug Safety's surveillance, criminal and administrative dispositions, and litigation for damages for GMP violations as a result of whistleblowing of arbitrary manufacturing by domestic mid-sized pharmaceutical companies A and B, etc.
Advised Hanmi Pharmaceutical on technology licensing agreements with Sanofi, Eli Lilly, Boehringer Ingelheim, and Janssen
Advice, Litigation and Disputes Regarding Healthcare Industry Regulations
Represented Samsung Medical Center in a lawsuit relating to its response to MERS
Represented pharmaceutical companies in a lawsuit relating to comprehensive reduction of medicine prices by the Ministry of Health and Welfare
Represented 36 pharmaceutical companies in a lawsuit against the National Health Insurance Service in connection with reimbursement for Valsartan
Responded to the Ministry of Food and Drug Safety's surveillance, criminal and administrative dispositions, and litigation for damages for GMP violations as a result of whistleblowing of arbitrary manufacturing by domestic mid-sized pharmaceutical companies A and B, etc.
Represented D, a domestic mid-sized pharmaceutical company, in litigation seeking revocation of the product approval cancellation, etc. regarding the national lot release approval for Botulax injection
Represented S, a large domestic pharmaceutical company, in litigation seeking revocation of the national health insurance drug price reduction based on non-recognition of kickbacks and illegal calculation of the reduction rate, etc. in relation to the adjustment for reduction of the maximum amount of drugs subject to kickbacks
Represented Yuhan Corporation in litigation related to the commitment regarding payment of royalties for the use of technology under the joint development agreement and consignment manufacturing agreement for drugs
Advised Daewoong Pharmaceutical on the dispute with the antidiarrheal (Smecta) powder licensor regarding suspension
Advised JW Holdings on responding to the measures taken by the Ministry of Food and Drug Safety for the violation of the permission for drugs
Advised Samsung Biologics on the Pharmaceutical Affairs Act and responding to the Ministry of Food and Drug Safety in relation to the relaxation of regulations on biopharmaceuticals
Reviewed the possibility of the Ministry of Food and Drug Safety's disposition regarding KGMP renewal for catheters of Edwards Lifesciences Korea
Advised Energizer Personal Care on responding to the Ministry of Food and Drug Safety’s investigation related to its product defects
Advised Boryung Pharmaceutical on reviewing the Ministry of Food and Drug Safety’s measures related to the report on suspension of production, import, and supply of pharmaceuticals
Represented C, a large domestic pharmaceutical company, in litigation seeking damages due to default, such as liquidated damages for delay in delivery under a joint development and product supply contract for rapid diagnostic equipment for COVID-19 antigen testing, and return of remaining advance payment
Advice on Legislation and Government Relations
Represented B, a large domestic pharmaceutical company, in a project to respond to the revision of the National Health Insurance Act and the Pharmaceutical Affairs Act
Advised C, a large domestic pharmaceutical company, on the certification standards for innovative pharmaceutical companies
Represented B and C, mid-sized pharmaceutical companies in Korea, in a project to respond to the revision of the Infectious Disease Control and Prevention Act, etc.
Represented L, a foreign medical device company, in a project for addition of national health checkup items
Reviewed the economic x-evaluation report for the drug for which an application for decision on eligibility for health care benefits has been filed for Japanese pharmaceutical company K and many others.
Inquired about the Ministry of Food and Drug Safety's authoritative interpretation of related laws such as the Pharmaceutical Affairs Act for domestic pharmaceutical company A and many others.
Advised Korean Research-based Pharmaceutical Industry Association on a project to respond to the revision of foreign drug price reference standards
Advised Korean Research-based Pharmaceutical Industry Association on a project to respond to the revision of the drug pricing system (PVA revision, IRP rex-evaluation, ATP revision, etc.)
Advised Korea Pharmaceutical and Bio-Pharma Manufacturers Association on the project for research on improving the drug pricing system
Advice on Technology Licensing and Healthcare Business Strategy
Advised Hanmi Pharmaceutical on technology licensing agreements with Sanofi, Eli Lilly, Boehringer Ingelheim, and Janssen
Advised Yuhan Corporation on the establishment of ImmuneOncia, a joint venture for anticancer drug research and development with Sorrento Therapeutics, a U.S. NASDAQ-listed pharmaceutical company
Advised GE Healthcare on the acquisition of VATECH’s mammography division
Advised Daewoong Pharmaceutical on the due diligence and negotiations for the acquisition of an Italian pharmaceutical company
Advised Hanmi Pharmaceutical on the investment in Spectrum Pharmaceuticals, a U.S. NASDAQ-listed pharmaceutical company
Advised Daewoong Pharmaceutical on the acquisition of HanAll Biopharma
Advised Hanmi Pharmaceutical on the investment in Allegro Ophthalmics, a U.S. ophthalmic drug development company
Advised Daewoong Pharmaceutical on the acquisition of Baifeng in China
Advised Hanmi Pharmaceutical on the acquisition of JVM
Advised on the listing of SK Biopharmaceuticals, HK inno.N, Psomagen, etc. on the KOSDAQ market of the Korea Exchange

Related Content

View more